A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

Also called NCT03099122

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 115 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03099122
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03099122. Allocation not applicable; no masking; primary purpose prevention. Start 2017-08-16 (actual); primary completion 2019-11-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
Acronym
START-DCD
Condition
End-stage Renal Disease
Intervention (Biological)
Rabbit Anti-thymocyte Immunoglobulin
Intervention (Drug)
Tacrolimus
Intervention (Drug)
Methylprednisolone
Intervention (Drug)
Mycophenolate mofetil
Intervention (Drug)
Mycophenolate Na
Intervention (Drug)
prednisone
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03099122
Content hash
a075e6091173955cce282a85a3c334274c4a885cc945c651fbec0cffd8ea2ab3